You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
第四批國家集採藥品5月21日起落地山東 平均降價52%
阿思達克 04-28 12:09
山東省醫保局印發《關於執行第四批國家組織集中帶量採購藥品中選結果的通知》,明確從5月21日開始,全省所有公立醫療機構、駐魯軍隊醫療機構以及自願參加的醫保定點社會辦醫療機構、醫保定點零售藥店,按照第四批國家組織集中帶量採購藥品(山東)中選結果,向患者銷售中選藥品。

據悉,國家第四批藥品集中採購共有45種藥品158個產品中選,涉及高血壓、糖尿病、消化道疾病、精神類疾病、惡性腫瘤等多種治療領域,平均降價52%。

據《大眾日報》報道,山東省建立藥品和醫用耗材集中帶量採購常態化機制,三批112個國家集採藥品平均降價60%以上,每年可節約藥費27.54億元人民幣。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account